ELCC 2026
The European Lung Cancer Congress is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.
Medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians / pneumologists, interventional radiologists and pathologists all benefit from its comprehensive and stimulating programme.
Make sure you connect to this highly interactive meeting and share your expertise with lung cancer specialists from all over the world.
Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?
Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC
The potential of T-cell engagers in SCLC treatment
Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma
Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer
Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality
Durvalumab improves survival and delays progression in limited-stage small cell lung cancer
Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer
Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC
Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance
SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer
Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer
Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer
Distinct lung microbiome patterns identified in Portuguese patients with lung cancer
Artificial intelligence PD-L1 scoring matches pathologists and improves reproducibility in lung cancer testing
T-cell engagers in lung cancer: Strategies to prevent and manage toxicities
Low-dose CT screening reduces lung cancer mortality and improves survival in broad populations
Cracking the code: Bispecific immunotherapy in small cell lung cancer
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC
Durvalumab after SBRT reduces tumour progression in early-stage NSCLC
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer